Mass spectrometry and CRISPR are pillars of drug discovery

<p class="MsoNormal"><span lang="EN" xml:lang="EN">This is the latest episode of the free DDW podcast, “Mass spectrometry and CRISPR are pillars of drug discovery”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “<a href= "https://www.ddw-online.com/how-asms-offers-more-than-seeing-what-sticks-15351-202201/">How ASMS offers more than seeing what sticks</a>” and “<a href= "https://www.ddw-online.com/crispr-screening-in-the-third-dimension-15362-202201/">CRISPR screening in the third dimension</a>”.</span></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">In the first article, Dr. Zack Gurard-Levin, Chief Scientific Officer at SAMDI Tech, breaks down three critical components to consider to ensure a successful affinity selection mass spectrometry (ASMS) drug discovery programme.</span></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">In the second article, Rosie Bryan & Carlos le Sage from Horizon Discovery, explain how CRISPR-Cas9 technology has become a gold standard for functional genomics.</span></p> <p class="MsoNormal"><span lang="EN" xml:lang="EN">You can also find The Drug Discovery World Podcast on <a href= "https://open.spotify.com/show/5HpeK1T3H1VQIB1fiwn0KQ">Spotify</a>, <a href= "https://podcasts.google.com/search/The%20Drug%20Discovery%20World%20Podcast"> Google Play</a> and <a href= "https://podcasts.apple.com/gb/podcast/the-drug-discovery-world-podcast/id1313272507"> Apple Podcasts</a>.</span></p> <p class="MsoNormal"><span lang="EN" xml:lang= "EN"> </span></p> <p class="MsoNormal"><span lang="EN" xml:lang= "EN"> </span></p> <p class="MsoNormal"><span lang="EN" xml:lang= "EN"> </span></p>